Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation …
West Japan Oncology Group - Journal of clinical …, 2022 - kyushu-u.elsevierpure.com
PURPOSE: To investigate the efficacy of gefitinib as an adjuvant therapy for non-small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS: IMPACT …
lung cancer patients with EGFR mutation. PATIENTS AND METHODS: IMPACT …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi… - Journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose To investigate the efficacy of gefitinib as an adjuvant therapy for non-small-cell lung
cancer patients with EGFR mutation. Patients and methods IMPACT (WJOG6410L; …
cancer patients with EGFR mutation. Patients and methods IMPACT (WJOG6410L; …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> To investigate the efficacy of
gefitinib as an adjuvant therapy for non–small-cell lung cancer patients with EGFR …
gefitinib as an adjuvant therapy for non–small-cell lung cancer patients with EGFR …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2021 - europepmc.org
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With
Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT) …
Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT) …